Learn how open APIs give durable medical equipment (DME) providers the control and flexibility to future-proof their tech stack. Legacy systems were built ...
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share. The company ...
Please provide your email address to receive an email when new articles are posted on . A large cohort study showed high prevalence of bilateral diabetic macular edema at first visit. The intensity of ...
Vor Biopharma (NASDAQ:VOR) trading was halted on September 18, 2025, pending any announcements from the company. The stock fell over 16% this week. Separately, 10% owner Reprogrammed Interchange and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback